Effects of Pioglitazone in Hypertensive Patients

Phase 4

Completed

• Conditions: Hypertension; Insulin Resistance
• Interventions: Drug: Pioglitazone

• Registration Number: NCT01472497
• Lead Sponsor: Tottori University Hospital

Brief Summary

Insulin resistance is often complicated with hypertension. AGE and inflammation play important roles in insulin resistance. Some studies reported that pioglitazone, insulin sensitizer, is effective for patients with insulin resistance, however, the mechanisms are still unclear. The aim of this study to evaluate the effect of pioglitazone compared with glimepiride on AGE, inflammatory cytokines and cardiac markers (BNP and echo) in hypertensive patients during oral glucose tolerance test.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-04
• Study First Submitted: 2011-07-21
• Study First Submitted QC: 2011-11-15
• Study First Posted: 2011-11-16
• Primary Completion: 2011-12
• Study Completion: 2012-03
• Status Verified: 2012-06
• Last Update Submitted: 2012-06-03
• Last Update Posted: 2012-06-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• Hypertension with insulin resistance

Exclusion Criteria

• Chronic systolic heart failure, ACS

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
glymepiride	Pioglitazone	-

Primary Outcome Measures

Name	Time	Method
advanced glycation end-product (AGE)	24 weeks
inflammatory cytokines (TNF-alfa, IL-6 and MCP-1)	24 weeks
cardiac function (echo and BNP)	24 weeks

Trial Locations

Locations (1)

Tottori University Hospital; 🇯🇵 Yonago, Japan